Article: Relevance of genetic polymorphism in drug metabolism in the development of new drugs

Drugs whose principal metabolic pathways are under polymorphic genetic regulation may show considerable interindividual pharmacokinetic variability. This could lead to clinically significant differences in the pharmacological responses of some patients and so might lead the pharmaceutical industry to stop development of the drug. This can be prevented and there are several measures that can be taken to avoid such premature termination of development. They include studies in vitro with human liver samples, and clinical pharmacological experiments designed specifically to examine possible genetic polymorphism in the disposition of the drug.

Citing Articles

Personalized medicine - where do we stand? Pouring some water into wine: a realistic perspective.

Gundert-Remy U, Dimovski A, Gajovic S Croat Med J. 2012; 53(4):314-20.

PMID: 22911523 PMC: 3428819. DOI: 10.3325/cmj.2012.53.314.

Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.

Feifel N, Kucher K, Fuchs L, Jedrychowski M, Schmidt E, Antonin K Eur J Clin Pharmacol. 1993; 45(3):265-9.

PMID: 8276052 DOI: 10.1007/BF00315394.

Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.

Anthony L, Boeve T, Hande K Cancer Chemother Pharmacol. 1995; 36(2):125-8.

PMID: 7767948 DOI: 10.1007/BF00689196.

Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.

Brosen K Clin Pharmacokinet. 1990; 18(3):220-39.

PMID: 2182263 DOI: 10.2165/00003088-199018030-00004.

Is there a need for more precise definitions of bioavailability? Conclusions of a consensus workshop, Munich, September 9, 1989; under the patronage of the F.I.P.

Eur J Clin Pharmacol. 1991; 40(2):123-6.

PMID: 2065692

References

1.

Lennard M, Tucker G, Woods H . The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1986; 11(1):1-17. DOI: 10.2165/00003088-198611010-00001. View

2.

Eichelbaum M . Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982; 7(1):1-22. DOI: 10.2165/00003088-198207010-00001. View

3.

Meier P, MUELLER H, Dick B, Meyer U . Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology. 1983; 85(3):682-92. View

4.

Sheiner L, Benet L . Premarketing observational studies of population pharmacokinetics of new drugs. Clin Pharmacol Ther. 1985; 38(5):481-7. DOI: 10.1038/clpt.1985.212. View

5.

Dayer P, Balant L, Kupfer A, Striberni R, Leemann T . Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur J Clin Pharmacol. 1985; 28(3):317-20. DOI: 10.1007/BF00543330. View

6.

von Bahr C, Groth C, Jansson H, Lundgren G, Lind M, Glaumann H . Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther. 1980; 27(6):711-25. DOI: 10.1038/clpt.1980.102. View

7.

Inaba T, Tyndale R, Mahon W . Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. Br J Clin Pharmacol. 1986; 22(2):199-200. PMC: 1401106. DOI: 10.1111/j.1365-2125.1986.tb05251.x. View

8.

Evans D, Mahgoub A, Sloan T, Idle J, Smith R . A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980; 17(2):102-5. PMC: 1048511. DOI: 10.1136/jmg.17.2.102. View

9.

Boobis A, Brodie M, Kahn G, Fletcher D, Saunders J, Davies D . Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol. 1980; 9(1):11-9. PMC: 1429924. DOI: 10.1111/j.1365-2125.1980.tb04790.x. View

10.

Speirs C, Murray S, Boobis A, Seddon C, Davies D . Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol. 1986; 22(6):739-43. PMC: 1401220. DOI: 10.1111/j.1365-2125.1986.tb02969.x. View

11.

Brosen K, Gram L, Klysner R, Bech P . Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. Eur J Clin Pharmacol. 1986; 30(1):43-9. DOI: 10.1007/BF00614194. View

Relevance of Genetic Polymorphism in Drug Metabolism in the Development of New Drugs